Silo’s SP-26 is a ketamine-based, injectable dissolvable implant for the treatment of chronic pain and fibromyalgia.
Silo Pharma said it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for the company’s implantable ketamine therapeutic.
Titled “Methods and Combinations for Managing Pain,” the patent application seeks protection for SP-26, “a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia,” according to the company.
“Our SP-26 implant technology is designed to deliver a steady, low dose of ketamine for sustained relief of chronic pain,” said Eric Weisblum, CEO of Silo. “We are pleased with the implant’s performance in pre-clinical studies to date. If approved, SP-26 could be the first at-home approved ketamine-based therapeutic.”
The next tests of the SP-26 ketamine implant will measure drug dissolution and time-release action, Silo noted.
Silo’s R&D programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore.